New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

Pharma Outsourcing – Find the Right Partner (2025)

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

Problem hos kontraktstillverkare stoppar Regenerons blodcancerläkemedel

För andra gången har Regeneron nekats godkännande i USA för en ny lymfombehandling. Orsaken uppges denna gång vara anmärkningar mot en extern tillverkningsanläg...

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

Meet us at Control 2025

Innovations that drive efficiency.

Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

Alvotech nobbas i USA efter brister i fabrik – dyker på börsen

Isländska Alvotech, noterade på Stockholmsbörsen, har fått ett bakslag i sin lansering av biosimilaren AVT05 i USA, en kandidat som ska motsvara läkemedlet Simponi (golimumab).

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

A cluster contribution to European life science innovation and competitiveness?

Nobelpristagare spår första AI-läkemedlet redan nästa år

De första AI-utvecklade läkemedlen kan börja prövas redan mot slutet av året. Det säger Demis Hassabis, Googles chef för Deepmind och medgrundare till Isomorphic Labs.

Novo Nordisk tells staff to return to office

At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate ...

The Future of Metrology is Coming to Your Region

Join our event series.

Över 1 300 sökte internationella forskarjobb i Lund – ”Vi noterar en USA-effekt”

Lunds storsatsning på internationell rekrytering av forskare har väckt stort gensvar – totalt 1 325 personer har sökt 25 utlysta tjänster.

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...

An increasing number of people are falling ill with TBE – “Much more research is needed”

Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...

Life science-bolag pitchade idéer i eget ”Draknästet”

Ett nytt event, arrangerat av Medicon Village, lockade investerare att höra presentationer från life science- och medtechbolag. ”Det fördes diskussioner om intr...

Trender inom life science 2025 – Del 2 AI

Artificiell intelligens blir ännu bättre på att tolka data och mer multimodal. Risker med den nya tekniken diskuteras samtidigt allt mer. Del två i serien med t...

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...